Employers Unknowingly Financing the Federal 340B Drug Pricing Program
Hidden costs in the 340B program are significantly inflating employer health care spending.
1The Hidden Employer Burden
Employers often assume pharmaceutical companies bear the full cost of the 340B program through steep discounts. However, employers and commercial insurers are effectively financing the majority of this safety net. When employees visit 340B-eligible facilities, health plans pay full price, forfeiting negotiated drug rebates that would otherwise reduce their overall healthcare costs.
2Diabetes Care Cost Analysis
A recent IQVIA analysis highlights the financial impact using diabetes care as a primary case study. In 2025, employers and commercial insurers lost $4.8 billion in drug rebates due to 340B claims. With total spread revenue reaching $7.1 billion, employers covered 68% of these costs, while drug manufacturers accounted for the remaining 32%.
3Exponential Program Growth
The 340B program has expanded rapidly without sufficient oversight or transparency mechanisms. Federal data indicates that discounted drug purchases surged from $53.7 billion in 2022 to $100 billion in 2025. Furthermore, the number of covered entities grew from 1,000 in 1992 to over 53,000 by 2023, with hospitals representing 87% of total volume.
4Contract Pharmacy Expansion
Contract pharmacy arrangements have significantly widened the program's reach, growing from 1,740 in 2010 to nearly 240,000 today. These third-party entities often receive a percentage of each transaction, creating incentives to steer providers toward more expensive medications. Notably, the five largest chain pharmacies currently manage approximately 77% of these complex 340B contract relationships.
5Defining Patient Eligibility
The 340B program lacks a formal, standardized definition for an eligible patient. This ambiguity allows for extreme scenarios where individuals could be claimed as 340B patients based on a single historical interaction, such as being born at a facility. This lack of clear criteria complicates accountability and contributes to the program's rising financial footprint.
6Charity Care Discrepancies
Despite the program's intent to support the vulnerable, data shows no clear correlation between 340B revenue and increased charity care. Large nonprofit hospitals, which benefit most from the program, report lower charity care spending than their for-profit counterparts. This raises significant questions regarding how billions in spread revenue are utilized across the healthcare sector.
7Systemic Financial Pressures
The U.S. faces a growing need for a healthcare safety net, with uninsured populations projected to rise by over 50% following recent policy changes. With over 40% of adults reporting medical debt, the national burden exceeds $200 billion. The 340B program remains essential, yet its current lack of transparency threatens its long-term sustainability.
8Call for Program Accountability
Employers are currently writing blank checks into a system that drives up premiums without clear benefit to patients. To ensure funds are used wisely, employers must demand greater transparency and accountability. Moving forward, stakeholders need to align the program's financial operations with its original mission of providing a reliable safety net for patients.
Original article: HR Dive — Employers Unknowingly Financing the Federal 340B Drug Pricing Program